A case of cup‐like blasts associated with B‐lymphoblastic leukemia without NPM1 and FLT3 internal tandem duplication mutations

eJHaem ◽  
2020 ◽  
Vol 1 (2) ◽  
pp. 589-592
Author(s):  
Jean‐Baptiste Rieu ◽  
Lucie Coster ◽  
Jill Corre ◽  
Suzanne Tavitian ◽  
Christian Recher ◽  
...  
Keyword(s):  
Tandem Duplication ◽  
Lymphoblastic Leukemia ◽  
Internal Tandem Duplication ◽  
Flt3 Internal Tandem Duplication

scholarly journals FLT3 INTERNAL TANDEM DUPLICATION AND D835 MUTATIONS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND ITS CLINICAL SIGNIFICANCE

2014 ◽  
Vol 6 (1) ◽  
pp. e2014038 ◽  
Author(s):  
Ghaleb Elyamany ◽  
Mohamed Awad ◽  
Omar Alsuhaibani ◽  
Kamal Fadalla ◽  
Omer Al Sharif ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Tyrosine Kinase ◽  
Tandem Duplication ◽  
Lymphoblastic Leukemia ◽  
Kinase Domain ◽  
Tyrosine Kinase Domain ◽  
Class Iii ◽  
Internal Tandem Duplication ◽  
Flt3 Mutations ◽  
Flt3 Internal Tandem Duplication

The fms-like tyrosine kinase 3 (FLT3) gene is a member of the class III receptor tyrosine kinase family, mutations of FLT3 were first described in 1997 and account for the most frequent molecular mutations in acute myeloid leukemia. No data currently exist regarding FLT3 mutations in Saudi acute lymphoblastic leukemia (ALL) patients as no study has reported for FLT3 mutations in Saudi ALL patients. In this retrospective study, we have examined a cohort of 77 ALL patients, to determine the prevalence of FLT3 mutations and the possible prognostic relevance of these mutations in ALL patients and did correlations to other biologic factors, such as karyotype, molecular mutations, and leukocyte count. FLT3 internal tandem duplication (ITD) mutations and point mutation in tyrosine kinase domain (D835) mutations were analyzed in ALL patients at diagnosis by polymerase chain reaction (PCR). 2 cases (2.6%, 2/77) were positive for FLT3 mutations, one was found to have FLT3/ITD and other was found to have FLT3/D835. Our findings suggest that FLT3 mutations were not common in Saudi ALL and did not affect clinical outcome.

scholarly journals AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia

Blood ◽  
2014 ◽  
Vol 123 (6) ◽  
pp. 905-913 ◽  
Author(s):  
Erika K. Keeton ◽  
Kristen McEachern ◽  
Keith S. Dillman ◽  
Sangeetha Palakurthi ◽  
Yichen Cao ◽  
...  
Keyword(s):  
Messenger Rna ◽  
Myeloid Leukemia ◽  
Tandem Duplication ◽  
Kinase Inhibitor ◽  
Wild Type ◽  
Internal Tandem Duplication ◽  
Rna Translation ◽  
Key Points ◽  
Messenger Rna Translation ◽  
Flt3 Internal Tandem Duplication

Key Points AZD1208 is a selective pan-Pim kinase inhibitor with efficacy in AML cells, xenografts, and Flt3-internal tandem duplication or Flt3 wild-type patient samples. AML cell growth inhibition is associated with suppression of p70S6K, 4EBP1 phosphorylation, and messenger RNA translation.

FLT3 Internal Tandem Duplication in Acute Myeloid Leukemia with Normal Karyotype

2007 ◽  
Vol 42 (3) ◽  
pp. 250 ◽  
Author(s):  
Sang-Ho Kim ◽  
Yeo-Kyeoung Kim ◽  
Il-Kwon Lee ◽  
Deog-Yeon Jo ◽  
Jong-Ho Won ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Tandem Duplication ◽  
Normal Karyotype ◽  
Internal Tandem Duplication ◽  
Flt3 Internal Tandem Duplication ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document